Get an alert when WORLDWIDE CLINICAL TRIALS LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-07-09 (in 2mo)

Last made up 2025-06-25

Watchouts

None on the register

Cash

£9M

+35.2% vs 2023

Net assets

£15M

+94.5% vs 2023

Employees

382

+13.7% vs 2023

Profit before tax

£10M

+291.5% vs 2023

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £184,757,024£208,559,262
Operating profit -£7,061,298£8,594,353
Profit before tax -£5,200,466£9,958,317
Net profit -£4,560,116£7,461,787
Cash £6,997,190£9,459,484
Total assets less current liabilities £9,343,829£16,596,665
Net assets £7,842,887£15,257,142
Equity £7,842,887£15,257,142
Average employees 336382
Wages £36,501,329£25,465,285

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin -3.8%4.1%
Net margin -2.5%3.6%
Return on capital employed -75.6%51.8%
Gearing (liabilities / total assets) 90.0%84.9%
Current ratio 0.99x1.08x
Interest cover -26.32x29.64x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 101
Reporting scope
Standalone (parent only)
Auditor
Cooper Parry Group Limited
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The Company had net current assets of £6,817,176 at 31 December 2024 (2023: net current liabilities of £448,576). In the directors' opinion, the Company can continue as a going concern in the light of the favourable trading outlook and the continued support that is available from the wider Worldwide Clinical Trials group.”

Group structure

  1. WORLDWIDE CLINICAL TRIALS LIMITED · parent
    1. WoWei Pharmaceutical Technology (Shanghai) Co, Ltd 100% · China
    2. Worldwide Clinical Trials UK Limited 100% · United Kingdom

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

5 active · 11 resigned

Name Role Appointed Born Nationality
DENTONS SECRETARIES LIMITED Corporate Secretary 2011-01-17
BOWSER, David Michael Director 2024-04-30 Apr 1967 American
LEWIS, Gabrielle Ann Director 2026-02-09 Oct 1984 American
MACDONALD, Alistair John Director 2026-02-09 Feb 1970 British
MERRIMAN, Anthony Jason Director 2024-04-30 Jul 1985 British
Show 11 resigned officers
Name Role Appointed Resigned
BUTLER, David Michael Secretary 2007-10-24 2023-12-12
SIMMONS, Samuel Secretary 2007-06-25 2007-10-24
MAWLAW SECRETARIES LIMITED Corporate Secretary 2007-10-24 2011-01-17
BENTON, Peter Scobee Director 2024-04-30 2026-02-09
BUTLER, David Michael Director 2007-10-24 2023-12-12
CARTA, Angelico Director 2009-01-20 2024-05-31
CUTLER, Neal Richard, Dr Director 2007-06-25 2009-01-20
DENVIR, Michael Roger Director 2007-10-24 2023-05-01
DORIGOTTI, Fabio Director 2009-01-20 2015-09-07
LEDERMAN, Barry Alan Director 2024-04-30 2024-10-04
SUFFREDINI, Peter Director 2009-01-20 2023-12-12

Ownership

Persons with significant control

No persons with significant control on record.

Filing timeline

Last 20 of 93 total filings

Date Type Category Description
2026-02-10 TM01 officers Termination director company with name termination date PDF
2026-02-09 TM01 officers Termination director company with name termination date PDF
2026-02-09 AP01 officers Appoint person director company with name date PDF
2026-02-09 AP01 officers Appoint person director company with name date PDF
2025-10-16 MR04 mortgage Mortgage satisfy charge full
2025-10-16 MR04 mortgage Mortgage satisfy charge full
2025-10-03 AA accounts Accounts with accounts type full
2025-06-25 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-12-23 AA accounts Accounts with accounts type full
2024-07-05 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-06-05 TM01 officers Termination director company with name termination date PDF
2024-06-05 TM02 officers Termination secretary company with name termination date PDF
2024-06-05 TM01 officers Termination director company with name termination date PDF
2024-06-05 AP01 officers Appoint person director company with name date PDF
2024-06-05 AP01 officers Appoint person director company with name date PDF
2024-06-05 AP01 officers Appoint person director company with name date PDF
2024-06-05 AP01 officers Appoint person director company with name date PDF
2024-06-04 TM01 officers Termination director company with name termination date PDF
2023-11-02 AA accounts Accounts with accounts type full
2023-07-07 CS01 confirmation-statement Confirmation statement with no updates PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
8

last 12 months

Capital events
0

last 24 months

Officers appointed
2

last 12 months

Officers resigned
1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page